Social Media Ideas for Amgen

Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress - Slideshow

Amgen Drug Meets Goals of Key Test in Common Autoimmune Disease With No Approved Meds

Amgen’s dazodalibep led to statistically significant and clinically meaningful results, according to preliminary Phase 3 results in Sjögren’s disease. This fusion protein could com...

Amgen reports a Phase 3 win with Sjögren’s drug candidate

Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against the tough-to-treat autoimmune disorder.

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

Amgen Tells 4th Circ. No Point In Keeping CareFirst Suit Alive

Amgen urged the Fourth Circuit to overrule a Virginia federal judge's refusal to dismiss CareFirst's lawsuit accusing it of unlawfully delaying biosimilar competition for Enbrel, a...

Amgen Inc. (AMGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?

One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability o...

AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot

Amgen: Why Rivals' Cholesterol Drug Fail Is Bad News For The Pharma (Rating Downgrade)

Bristol-Myers Looks To Block Amgen's Cancer Biosimilar

Bristol-Myers Squibb Co. has sued rival Amgen Inc., seeking a court order blocking the manufacture of a biosimilar to the cancer drug Opdivo while patent rights on the drug's makeu...

ANC

ANC Anonymous (not verified) Mon, 09/14/2026 - 18:53 field_thread_url https://cafepharma.com/boards/threads/anc.712901/ board name...

Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

Amgen boasts stronger revenue growth, while Bristol Myers Squibb generates nearly 60% more free cash flow at half the valuation.

New data could widen use of AstraZeneca, Amgen immune disease drug

Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.

Argenx

Argenx Anonymous (not verified) Mon, 10/19/2026 - 10:14 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Genentech, Novartis Sue Amneal Over Bid To Sell Xolair Copy

Genentech Inc. and Novartis Pharmaceuticals Corp. have filed a patent infringement suit in Delaware federal court, claiming Kashiv BioSciences' bid to sell a biosimilar copy of the...

Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?

Amgen trades at half the valuation multiple of Eli Lilly while generating stronger free cash flow, but explosive growth in obesity drugs tells a different story.

<![CDATA[Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Cl...

AstraZeneca, Amgen Drug Moves Closer to Competing With Dupixent in a New Indication

AstraZeneca and Amgen drug Tezspire met the goals of a Phase 3 test in eosinophilic esophagitis (EoE), a chronic disorder whose only approved biologic therapy is Sanofi’s Dupixent....

<![CDATA[Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTe...

Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use

Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gen...

<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...

Genmab

Genmab Anonymous (not verified) Sat, 10/10/2026 - 07:10 field_thread_url https://cafepharma.com/boards/threads/genmab.680642/ board name...

<![CDATA[Roundup: Nanexa, Earendil Labs, and Atavistik Bio Enter Platform Deals with Novo Nordisk, Genentech, and Roc...

Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know